65,437 trials
Glaucoma · Ocular Hypertension
Primary: Intraocular Pressure (IOP) in the Study Eye at 8 AM, 12 PM, and 4 PM — 16.4; 15.1; 16.0; 15.0 Millimeters of Mercury (mmHg)
Age-Related Macular Degeneration · Geographic Atrophy · Diabetic Retinopathy
Primary: Standard Deviation and Mean Test Results of Normal and With Pathology Participants Taken by 3 Different Operator-device Configurations — 16.16; 12.23 decibels
Lung Cancer
Primary: The Difference of Diagnostic Value of ENB-GS-TBLB as Compared to GS-TBLB — 34; 25; 5; 16 participants — p=0.019
HIV, Pediatric
Primary: Number of Participants Who Died and With Serious Adverse Events (SAEs), Adverse Events (AEs) Leading to Discontinuation, Grade 2-4 Related AEs, Grade 3-4 AEs, and…
Bioequivalence, AUC, Cmax, Pharmacokinetics
Primary: Pharmacokinetics of Clopidogrel by Assessment of Area Under the Curve From Time Zero Extrapolated to Infinity (AUC(0-inf)) — 1.05; 0.992; 1.09 ng*h/mL
Dementia With Lewy Bodies (DLB)
Primary: Change From Baseline in Mini-Mental State Examination (MMSE) Score — 0.6; 1.4; 2.2 Units on a scale
Cancer
Primary: Psychological Distress — 2.25; -.65 units on a scale — p=0.14
Influenza
Primary: Efficacy, Measured by the Number of Subjects With a Change in Innate Immune Signatures — 22; 44 participants
Onychomycosis
Primary: Mycological Cure — 17; 28; 16; 13 Percentage of participants — p=<0.05
Asthma · Rhinitis · Sinusitis
Primary: Asthma Control Test (ACT) — 2.95; 2.44 units on a scale
Ileostomy
Primary: Product Acceptance — 0; 1 participants
Myocardial Ischemia · Acute Coronary Syndrome · Heart Disease
Primary: CR Program Adherence — 54.40; 51.33; 58.12 percentage of sessions attended
Hepatitis C
Primary: Maximum Observed Plasma Concentration (Cmax) for Daclatasvir — 1335; 493; 1412; 476 ng/mL
Non-alcoholic Fatty Liver Disease · Nonalcoholic Steatohepatitis
Primary: Median Total Specimen Length — 8; 14; 8; 11.5 mm
Electromagnetic Interference
Primary: Electromagnetic Interference — 0 participants